Nov 24 (Reuters) - Life sciences firm Agilent

Technologies ( A ) on Monday beat fourth-quarter revenue

estimates, helped by strong demand for medical tools and

equipment used in lab research and diagnostic services.

The laboratory equipment maker also forecast revenue for

financial year 2026, which started in November, slightly ahead

of Wall Street expectations.

Agilent ( A ) sees 2026 revenue to be between $7.3 billion and

$7.4 billion, the midpoint of which is ahead of average analyst

estimates of $7.30 billion, according to data compiled by LSEG.

Medical equipment makers have seen renewed demand for

contract research and diagnostics services, as pharmaceutical

companies accelerate drug development in the U.S. amid President

Donald Trump's shifting trade policies.

The company's fourth-quarter revenue came in at $1.86

billion, beating estimates of $1.83 billion.

Sales in its life sciences and diagnostics segment were at

$755 million, beating the estimate of $718 million, while

revenue from its CrossLab unit, which offers products and

services for laboratory management, rose 7% to $775 million.

Its adjusted profit for the quarter ended October 31 was

$1.59 per share compared to estimates of $1.58 per share.